Tag Archives: SBOTF

News out on Steller Biotechnologies as it announces an Exclusive Agreement

Stellar Biotechnologies Acquires Exclusive, Worldwide License to Clostridium Difficile Immunotherapy Technology PORT HUENEME, CA– Stellar Biotechnologies, Inc. (“Stellar” or “the Company”) (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has acquired the exclusive, worldwide license to patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”) from the UniversityREAD FULL POSTREAD FULL POST

News and Key Alerts

Tag Archives: SBOTF

News out on Steller Biotechnologies as it announces an Exclusive Agreement

STELLAR-LOGO

Stellar Biotechnologies Acquires Exclusive, Worldwide License to Clostridium Difficile Immunotherapy Technology

PORT HUENEME, CA– Stellar Biotechnologies, Inc. (“Stellar” or “the Company”) (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has acquired the exclusive, worldwide license to patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”) from the University of Guelph (Ontario, Canada) (“Guelph”).

The license gives Stellar exclusive rights to develop, manufacture and sell human vaccines to treat C. diff infection that derive from technology covered by Guelph patents. The license also includes human diagnostic applications. Specifically, the agreement covers a family of international patents and patent applications related to the cell-wall polysaccharide of C. diff named PSII.

UP NEXT: STELLAR’S PRESIDENT AND CEO FRANK OAKES COMMENTS:Continue Reading

Sign-up for Free StockGuru Email Alerts

Subscribe to Live Updates From StockGuru
Subscribe

Get Email Alerts